This is a prospective, multicenter phase II clinical study. The subjects are patients with previously untreated locally advanced nasopharyngeal carcinoma, with clinical staging of IVA, T1-4, N3, M0. The study aims to preliminarily evaluate the efficacy and safety of Iparomlimab and Tuvonralimab Injectionin the treatment of these patients.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
3-year distant metastasis-free survival (DMFS) as assessed by imaging examinations (including CT, MRI, PET-CT) and clinical evaluations to determine the time from randomization to the first occurrence of distant metastasis or death from any cause
Timeframe: Up to 3 years after enrollment (each follow-up cycle is 3 months for the first two years, 6 months for the third year)
Objective response rate (ORR) of the tumor as assessed by RECIST 1.1 criteria, including complete response (CR) and partial response (PR) confirmed by imaging examinations (CT, MRI)
Timeframe: Every 9 weeks during treatment (each treatment cycle is 3 weeks) and at the end of treatment